Aicardi-Goutieres Syndrome 7 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AGS7 MCID: ACR084 MIFTS: 30	Aicardi-Goutieres Syndrome 7 (AGS7) Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Publications Symptoms & Phenotypes Expand all tables

Sources

Aliases & Classifications for Aicardi-Goutieres Syndrome 7

MalaCards integrated aliases for Aicardi-Goutieres Syndrome 7:

Name: Aicardi-Goutieres Syndrome 7 ⁵⁷ ⁷² ²⁹ ⁶ ⁷⁰

Ags7 ⁵⁷ ⁷²

Aicardi-Goutieres Syndrome, Type 7 ³⁹

Characteristics:

OMIM®:

⁵⁷ (Updated 20-May-2021)

Miscellaneous:
incomplete penetrance
variable severity
onset in infancy or early childhood

Inheritance:
autosomal dominant

HPO:

³¹

aicardi-goutieres syndrome 7:
Inheritance autosomal dominant inheritance
Onset and clinical course variable expressivity incomplete penetrance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Bone diseases Blood diseases Immune diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 615846

OMIM Phenotypic Series ⁵⁷ PS225750

MeSH ⁴⁴ D009421 D020274

MedGen ⁴¹ C3888244 CN188935

UMLS ⁷⁰ C3888244

Sources

Summaries for Aicardi-Goutieres Syndrome 7

OMIM® : ⁵⁷ Aicardi-Goutieres syndrome-7 (AGS7) is an autosomal dominant inflammatory disorder characterized by severe neurologic impairment. Most patients present in infancy with delayed psychomotor development, axial hypotonia, spasticity, and brain imaging changes, including basal ganglia calcification, cerebral atrophy, and deep white matter abnormalities. Laboratory evaluation shows increased alpha-interferon (IFNA1; 147660) activity with upregulation of interferon signaling and interferon-stimulated gene expression. Some patients may have normal early development followed by episodic neurologic regression (summary by Rice et al., 2014). For a phenotypic description and a discussion of genetic heterogeneity of Aicardi-Goutieres syndrome, see AGS1 (225750). (615846) (Updated 20-May-2021)

MalaCards based summary : Aicardi-Goutieres Syndrome 7, is also known as ags7. An important gene associated with Aicardi-Goutieres Syndrome 7 is IFIH1 (Interferon Induced With Helicase C Domain 1). Affiliated tissues include eye and brain, and related phenotypes are abnormality of eye movement and developmental regression

UniProtKB/Swiss-Prot : ⁷² Aicardi-Goutieres syndrome 7: A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

Sources

Related Diseases for Aicardi-Goutieres Syndrome 7

Diseases in the Aicardi-Goutieres Syndrome family:

Aicardi-Goutieres Syndrome 1	Aicardi-Goutieres Syndrome 2
Aicardi-Goutieres Syndrome 3	Aicardi-Goutieres Syndrome 4
Aicardi-Goutieres Syndrome 5	Aicardi-Goutieres Syndrome 6
Aicardi-Goutieres Syndrome 7

Sources

Symptoms & Phenotypes for Aicardi-Goutieres Syndrome 7

Human phenotypes related to Aicardi-Goutieres Syndrome 7:

³¹ (show all 23)

#	Description	HPO Frequency	HPO Source Accession
1	abnormality of eye movement ³¹	occasional (7.5%)	HP:0000496
2	developmental regression ³¹	occasional (7.5%)	HP:0002376
3	splenomegaly ³¹	occasional (7.5%)	HP:0001744
4	hepatomegaly ³¹	occasional (7.5%)	HP:0002240
5	microcephaly ³¹	occasional (7.5%)	HP:0000252
6	thrombocytopenia ³¹	occasional (7.5%)	HP:0001873
7	nephrotic syndrome ³¹	occasional (7.5%)	HP:0000100
8	seizure ³¹	occasional (7.5%)	HP:0001250
9	increased circulating antibody level ³¹	occasional (7.5%)	HP:0010702
10	intellectual disability ³¹		HP:0001249
11	global developmental delay ³¹		HP:0001263
12	absent speech ³¹		HP:0001344
13	intrauterine growth retardation ³¹		HP:0001511
14	irritability ³¹		HP:0000737
15	dystonia ³¹		HP:0001332
16	vasculitis ³¹		HP:0002633
17	feeding difficulties ³¹		HP:0011968
18	spastic tetraparesis ³¹		HP:0001285
19	cerebral atrophy ³¹		HP:0002059
20	generalized hypotonia ³¹		HP:0001290
21	muscular hypotonia of the trunk ³¹		HP:0008936
22	atopic dermatitis ³¹		HP:0001047
23	basal ganglia calcification ³¹		HP:0002135

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 20-May-2021)

Neurologic Central Nervous System:
dystonia
cerebral atrophy
basal ganglia calcification
mental retardation
seizures (in some patients)
more

Muscle Soft Tissue:
hypotonia

Hematology:
thrombocytopenia (in some patients)

Growth Other:
intrauterine growth retardation (iugr)

Abdomen Spleen:
splenomegaly (in some patients)

Head And Neck Eyes:
abnormal ocular movements (in some patients)

Skin Nails Hair Skin:
vasculitis
atopic dermatitis
lack of chilblain lesions

Abdomen Gastrointestinal:
poor feeding

Head And Neck Head:
microcephaly (in some patients)

Abdomen Liver:
hepatomegaly (in some patients)

Immunology:
upregulation of alpha-interferon-stimulated genes
autoantibodies (in some patients)
lupus-like syndrome (in some patients)
hyperinflammatory state
increased alpha-interferon activity
more

Genitourinary Kidneys:
nephrotic syndrome (1 patient)

Clinical features from OMIM®:

615846 (Updated 20-May-2021)

Sources

Drugs & Therapeutics for Aicardi-Goutieres Syndrome 7

Search Clinical Trials , NIH Clinical Center for Aicardi-Goutieres Syndrome 7

Sources

Genetic Tests for Aicardi-Goutieres Syndrome 7

Genetic tests related to Aicardi-Goutieres Syndrome 7:

#	Genetic test	Affiliating Genes
1	Aicardi-Goutieres Syndrome 7 ²⁹	IFIH1

Sources

Anatomical Context for Aicardi-Goutieres Syndrome 7

MalaCards organs/tissues related to Aicardi-Goutieres Syndrome 7:

⁴⁰

Eye, Brain

Sources

Publications for Aicardi-Goutieres Syndrome 7

Articles related to Aicardi-Goutieres Syndrome 7:

(show all 15)

#	Title	Authors	PMID	Year
1	An extremely severe case of Aicardi-Goutières syndrome 7 with a novel variant in IFIH1. ⁶ ⁵⁷ ⁶¹	Amari S...Ito Y	30965144	2020
2	Aicardi goutières syndrome is associated with pulmonary hypertension. ⁵⁷ ⁶	Adang LA...Vanderver AL	30219631	2018
3	Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. ⁶ ⁵⁷	Crow YJ...Rice GI	25243380	2014
4	Aicardi-Goutières syndrome is caused by IFIH1 mutations. ⁶ ⁵⁷	Oda H...Heike T	24995871	2014
5	Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. ⁶ ⁵⁷	Rice GI...Crow YJ	24686847	2014
6	Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. ⁶	Rice GI...Crow YJ	31898846	2020
7	Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis. ⁶	Galli J...AGS study group	30593198	2018
8	Autosomal-dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. ⁶	Ruaud L...Van Maldergem L	29782060	2018
9	Musculoskeletal Disease in MDA5-Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy. ⁶	de Carvalho LM...Crow YJ	28605144	2017
10	Further evidence for specific IFIH1 mutation as a cause of Singleton-Merten syndrome with phenotypic heterogeneity. ⁶	Pettersson M...Lindstrand A	28319323	2017
11	Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes. ⁶	Bursztejn AC...Crow YJ	26284909	2015
12	A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. ⁶	Rutsch F...Hennekam RC	25620204	2015
13	Biomarkers and Precision Therapy for Primary Immunodeficiencies: An In Vitro Study Based on Induced Pluripotent Stem Cells From Patients. ⁶¹	Genova E...Stocco G	32243572	2020
14	Generation of three isogenic induced Pluripotent Stem Cell lines (iPSCs) from fibroblasts of a patient with Aicardi Goutières Syndrome carrying a c.2471G>A dominant mutation in IFIH1 gene. ⁶¹	Masneri S...Giliani S	31698194	2019
15	Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières Syndrome and Beyond. ⁶¹	Livingston JH...Crow YJ	27643693	2016

Sources

Genes for Aicardi-Goutieres Syndrome 7

Genes related to Aicardi-Goutieres Syndrome 7 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IFIH1	Interferon Induced With Helicase C Domain 1	Protein Coding	1345.74	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷² Genetic Tests ²⁹ Likely pathogenic ⁶ GeneCards inferred via : Disorders Variants (show sections)	24686847

Sources

Variations for Aicardi-Goutieres Syndrome 7

ClinVar genetic disease variations for Aicardi-Goutieres Syndrome 7:

⁶ (show top 50) (show all 314)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	IFIH1	NM_022168.4(IFIH1):c.2159G>A (p.Arg720Gln)	SNV	Pathogenic	137621	rs587777445	GRCh37: 2:163133342-163133342 GRCh38: 2:162276832-162276832
2	IFIH1	NM_022168.4(IFIH1):c.2336G>A (p.Arg779His)	SNV	Pathogenic	137622	rs587777446	GRCh37: 2:163130423-163130423 GRCh38: 2:162273913-162273913
3	IFIH1	NM_022168.4(IFIH1):c.1009A>G (p.Arg337Gly)	SNV	Pathogenic	137623	rs587777447	GRCh37: 2:163144731-163144731 GRCh38: 2:162288221-162288221
4	IFIH1	NM_022168.4(IFIH1):c.2335C>T (p.Arg779Cys)	SNV	Pathogenic	137624	rs587777448	GRCh37: 2:163130424-163130424 GRCh38: 2:162273914-162273914
5	IFIH1	NM_022168.4(IFIH1):c.1483G>A (p.Gly495Arg)	SNV	Pathogenic	137625	rs672601336	GRCh37: 2:163137879-163137879 GRCh38: 2:162281369-162281369
6	IFIH1	NM_022168.4(IFIH1):c.1354G>A (p.Ala452Thr)	SNV	Pathogenic	140750	rs587777575	GRCh37: 2:163138008-163138008 GRCh38: 2:162281498-162281498
7	IFIH1	NM_022168.4(IFIH1):c.1114C>T (p.Leu372Phe)	SNV	Pathogenic	140751	rs587777576	GRCh37: 2:163139068-163139068 GRCh38: 2:162282558-162282558
8	IFIH1	NM_022168.4(IFIH1):c.1738C>T (p.Gln580Ter)	SNV	Pathogenic	587512	rs774888783	GRCh37: 2:163134742-163134742 GRCh38: 2:162278232-162278232
9	IFIH1	NM_022168.4(IFIH1):c.2465G>A (p.Arg822Gln)	SNV	Pathogenic	189338	rs376048533	GRCh37: 2:163128887-163128887 GRCh38: 2:162272377-162272377
10	IFIH1	NM_022168.4(IFIH1):c.2465G>A (p.Arg822Gln)	SNV	Pathogenic	189338	rs376048533	GRCh37: 2:163128887-163128887 GRCh38: 2:162272377-162272377
11	IFIH1	NM_022168.4(IFIH1):c.2439A>T (p.Glu813Asp)	SNV	Pathogenic	623488	rs1559810905	GRCh37: 2:163130320-163130320 GRCh38: 2:162273810-162273810
12	IFIH1	NM_022168.4(IFIH1):c.2336G>A (p.Arg779His)	SNV	Pathogenic	137622	rs587777446	GRCh37: 2:163130423-163130423 GRCh38: 2:162273913-162273913
13	IFIH1	NM_022168.4(IFIH1):c.2342G>A (p.Gly781Glu)	SNV	Pathogenic	812533	rs1576222845	GRCh37: 2:163130417-163130417 GRCh38: 2:162273907-162273907
14	IFIH1	NM_022168.4(IFIH1):c.2404A>G (p.Asn802Asp)	SNV	Pathogenic	812534	rs1576222803	GRCh37: 2:163130355-163130355 GRCh38: 2:162273845-162273845
15	IFIH1	NM_022168.4(IFIH1):c.2407A>T (p.Ile803Phe)	SNV	Pathogenic	812535	rs774958328	GRCh37: 2:163130352-163130352 GRCh38: 2:162273842-162273842
16	IFIH1	NM_022168.4(IFIH1):c.2471G>A (p.Arg824Lys)	SNV	Pathogenic	812536	rs1238832404	GRCh37: 2:163128881-163128881 GRCh38: 2:162272371-162272371
17	IFIH1	NM_022168.4(IFIH1):c.2486C>G (p.Thr829Ser)	SNV	Pathogenic	812537	rs765887304	GRCh37: 2:163128866-163128866 GRCh38: 2:162272356-162272356
18	IFIH1	NM_022168.4(IFIH1):c.2544T>G (p.Asp848Glu)	SNV	Pathogenic	812538	rs1576222015	GRCh37: 2:163128808-163128808 GRCh38: 2:162272298-162272298
19	IFIH1	NM_022168.4(IFIH1):c.2561T>A (p.Met854Lys)	SNV	Pathogenic	812539	rs138373022	GRCh37: 2:163128791-163128791 GRCh38: 2:162272281-162272281
20	IFIH1	NM_022168.4(IFIH1):c.2866A>G (p.Ile956Val)	SNV	Pathogenic	812540	rs1576219706	GRCh37: 2:163124021-163124021 GRCh38: 2:162267511-162267511
21	IFIH1	NM_022168.4(IFIH1):c.1764dup (p.Ala589fs)	Duplication	Pathogenic	541791	rs553669430	GRCh37: 2:163134715-163134716 GRCh38: 2:162278205-162278206
22	IFIH1	NM_022168.4(IFIH1):c.992C>G (p.Thr331Arg)	SNV	Pathogenic	812522	rs1576229572	GRCh37: 2:163144748-163144748 GRCh38: 2:162288238-162288238
23	IFIH1	NM_022168.4(IFIH1):c.992C>T (p.Thr331Ile)	SNV	Pathogenic	812523	rs1576229572	GRCh37: 2:163144748-163144748 GRCh38: 2:162288238-162288238
24	IFIH1	NM_022168.4(IFIH1):c.1165G>A (p.Gly389Arg)	SNV	Pathogenic	812524	rs1576227162	GRCh37: 2:163139017-163139017 GRCh38: 2:162282507-162282507
25	IFIH1	NM_022168.4(IFIH1):c.1178A>C (p.Asp393Ala)	SNV	Pathogenic	812525	rs587777449	GRCh37: 2:163139004-163139004 GRCh38: 2:162282494-162282494
26	IFIH1	NM_022168.4(IFIH1):c.1331A>G (p.Glu444Gly)	SNV	Pathogenic	812526	rs1576226728	GRCh37: 2:163138031-163138031 GRCh38: 2:162281521-162281521
27	IFIH1	NM_022168.4(IFIH1):c.1347C>G (p.Asn449Lys)	SNV	Pathogenic	812527	rs753383954	GRCh37: 2:163138015-163138015 GRCh38: 2:162281505-162281505
28	IFIH1	NM_022168.4(IFIH1):c.1465G>A (p.Ala489Thr)	SNV	Pathogenic	812528	rs1576226604	GRCh37: 2:163137897-163137897 GRCh38: 2:162281387-162281387
29	IFIH1	NM_022168.4(IFIH1):c.1747A>G (p.Ile583Val)	SNV	Pathogenic	812529	rs753599401	GRCh37: 2:163134733-163134733 GRCh38: 2:162278223-162278223
30	IFIH1	NM_022168.4(IFIH1):c.2156C>T (p.Ala719Val)	SNV	Pathogenic	812530	rs1576224269	GRCh37: 2:163133345-163133345 GRCh38: 2:162276835-162276835
31	IFIH1	NM_022168.4(IFIH1):c.2317G>C (p.Glu773Gln)	SNV	Pathogenic	812531	rs201472224	GRCh37: 2:163130442-163130442 GRCh38: 2:162273932-162273932
32	IFIH1	NM_022168.4(IFIH1):c.2016del (p.Asp673fs)	Deletion	Pathogenic	580488	rs773033563	GRCh37: 2:163133953-163133953 GRCh38: 2:162277443-162277443
33	IFIH1	NM_022168.4(IFIH1):c.713G>A (p.Trp238Ter)	SNV	Pathogenic	1032134		GRCh37: 2:163163275-163163275 GRCh38: 2:162306765-162306765
34	IFIH1	NM_022168.4(IFIH1):c.2016_2019AGAT[1] (p.Arg674fs)	Microsatellite	Pathogenic	377097	rs569337014	GRCh37: 2:163133946-163133949 GRCh38: 2:162277436-162277439
35	IFIH1	NM_022168.4(IFIH1):c.1517T>A (p.Ile506Asn)	SNV	Likely pathogenic	626276	rs1320095792	GRCh37: 2:163137845-163137845 GRCh38: 2:162281335-162281335
36	IFIH1	NM_022168.4(IFIH1):c.2336G>T (p.Arg779Leu)	SNV	Likely pathogenic	812532	rs587777446	GRCh37: 2:163130423-163130423 GRCh38: 2:162273913-162273913
37	IFIH1	NM_022168.4(IFIH1):c.716dup (p.Met240fs)	Duplication	Likely pathogenic	587596	rs1558875029	GRCh37: 2:163163271-163163272 GRCh38: 2:162306761-162306762
38	IFIH1	NM_022168.4(IFIH1):c.986T>C (p.Leu329Pro)	SNV	Likely pathogenic	577615	rs923064561	GRCh37: 2:163144754-163144754 GRCh38: 2:162288244-162288244
39	IFIH1	NM_022168.4(IFIH1):c.1178A>T (p.Asp393Val)	SNV	Likely pathogenic	137626	rs587777449	GRCh37: 2:163139004-163139004 GRCh38: 2:162282494-162282494
40	IFIH1	NM_022168.4(IFIH1):c.2936T>G (p.Leu979Trp)	SNV	Likely pathogenic	541770	rs1553696482	GRCh37: 2:163123852-163123852 GRCh38: 2:162267342-162267342
41	IFIH1	NM_022168.4(IFIH1):c.2524G>A (p.Glu842Lys)	SNV	Conflicting interpretations of pathogenicity	474952	rs79324540	GRCh37: 2:163128828-163128828 GRCh38: 2:162272318-162272318
42	IFIH1	NM_022168.4(IFIH1):c.1641+1G>C	SNV	Conflicting interpretations of pathogenicity	261563	rs35337543	GRCh37: 2:163136505-163136505 GRCh38: 2:162279995-162279995
43	IFIH1	NM_022168.4(IFIH1):c.1066C>A (p.Pro356Thr)	SNV	Conflicting interpretations of pathogenicity	541784	rs150317197	GRCh37: 2:163144674-163144674 GRCh38: 2:162288164-162288164
44	IFIH1	NM_022168.4(IFIH1):c.2362G>A (p.Ala788Thr)	SNV	Conflicting interpretations of pathogenicity	541788	rs148369169	GRCh37: 2:163130397-163130397 GRCh38: 2:162273887-162273887
45	IFIH1	NM_022168.4(IFIH1):c.478A>G (p.Asn160Asp)	SNV	Conflicting interpretations of pathogenicity	625959	rs74162075	GRCh37: 2:163167419-163167419 GRCh38: 2:162310909-162310909
46	IFIH1	NM_022168.4(IFIH1):c.2863C>G (p.Gln955Glu)	SNV	Conflicting interpretations of pathogenicity	705603	rs144455277	GRCh37: 2:163124024-163124024 GRCh38: 2:162267514-162267514
47	IFIH1	NM_022168.4(IFIH1):c.1879G>T (p.Glu627Ter)	SNV	Conflicting interpretations of pathogenicity	377048	rs35744605	GRCh37: 2:163134090-163134090 GRCh38: 2:162277580-162277580
48	IFIH1	NM_022168.4(IFIH1):c.1764del (p.Ala589fs)	Deletion	Uncertain significance	987915		GRCh37: 2:163134716-163134716 GRCh38: 2:162278206-162278206
49	IFIH1	NM_022168.4(IFIH1):c.769+3A>G	SNV	Uncertain significance	987916		GRCh37: 2:163163216-163163216 GRCh38: 2:162306706-162306706
50	IFIH1	NM_022168.4(IFIH1):c.2321T>A (p.Val774Asp)	SNV	Uncertain significance	996881		GRCh37: 2:163130438-163130438 GRCh38: 2:162273928-162273928

UniProtKB/Swiss-Prot genetic disease variations for Aicardi-Goutieres Syndrome 7:

⁷²

#	Symbol	AA change	Variation ID	SNP ID
1	IFIH1	p.Arg337Gly	VAR_071375	rs587777447
2	IFIH1	p.Leu372Phe	VAR_071376	rs587777576
3	IFIH1	p.Asp393Val	VAR_071377	rs587777449
4	IFIH1	p.Ala452Thr	VAR_071378	rs587777575
5	IFIH1	p.Gly495Arg	VAR_071379	rs672601336
6	IFIH1	p.Arg720Gln	VAR_071380	rs587777445
7	IFIH1	p.Arg779Cys	VAR_071381	rs587777448
8	IFIH1	p.Arg779His	VAR_071382	rs587777446

Sources

Expression for Aicardi-Goutieres Syndrome 7

Search GEO for disease gene expression data for Aicardi-Goutieres Syndrome 7.

Sources

Pathways for Aicardi-Goutieres Syndrome 7

Sources

GO Terms for Aicardi-Goutieres Syndrome 7

Sources

Sources for Aicardi-Goutieres Syndrome 7

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 20-May-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Aicardi-Goutieres Syndrome 7 (AGS7)

Aliases & Classifications for Aicardi-Goutieres Syndrome 7

MalaCards integrated aliases for Aicardi-Goutieres Syndrome 7:

Characteristics:

OMIM®:

HPO:

Classifications:

External Ids:

Summaries for Aicardi-Goutieres Syndrome 7

Related Diseases for Aicardi-Goutieres Syndrome 7

Diseases in the Aicardi-Goutieres Syndrome family:

Symptoms & Phenotypes for Aicardi-Goutieres Syndrome 7

Human phenotypes related to Aicardi-Goutieres Syndrome 7:

Symptoms via clinical synopsis from OMIM®:

Clinical features from OMIM®:

Drugs & Therapeutics for Aicardi-Goutieres Syndrome 7

Genetic Tests for Aicardi-Goutieres Syndrome 7

Genetic tests related to Aicardi-Goutieres Syndrome 7:

Anatomical Context for Aicardi-Goutieres Syndrome 7

MalaCards organs/tissues related to Aicardi-Goutieres Syndrome 7:

Publications for Aicardi-Goutieres Syndrome 7

Articles related to Aicardi-Goutieres Syndrome 7:

Genes for Aicardi-Goutieres Syndrome 7

Genes related to Aicardi-Goutieres Syndrome 7 (1 elite genes):

Variations for Aicardi-Goutieres Syndrome 7

ClinVar genetic disease variations for Aicardi-Goutieres Syndrome 7:

UniProtKB/Swiss-Prot genetic disease variations for Aicardi-Goutieres Syndrome 7:

Expression for Aicardi-Goutieres Syndrome 7

Pathways for Aicardi-Goutieres Syndrome 7

GO Terms for Aicardi-Goutieres Syndrome 7

Sources for Aicardi-Goutieres Syndrome 7